Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- XERS
- Price
- 7.61
- Stock movement down
- -0.01 (-0.13%)
- Company name
- Xeris Pharmaceuticals Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 1.26B
- Ent value
- 1.54B
- Price/Sales
- 4.74
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- 24.20
- PEG
- -
- EPS growth
- -40.01%
- 1 year return (CAGR)
- 127.84%
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-01-22
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
XERS does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | 119.59 |
| Price to FCF | 126.92 |
| Price to EBITDA | 82.53 |
| EV to EBITDA | 100.80 |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 4.74 |
| Price to Book | - |
| EV to Sales | 5.79 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 165.92M |
| EPS (TTM) | -0.09 |
| FCF per share (TTM) | 0.06 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 266.14M |
| Gross profit (TTM) | 158.94M |
| Operating income (TTM) | 9.80M |
| Net income (TTM) | -15.64M |
| EPS (TTM) | -0.09 |
| EPS (1y forward) | 0.31 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 59.72% |
| Operating margin (TTM) | 3.68% |
| Profit margin (TTM) | -5.88% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 91.60M |
| Net receivables | 53.75M |
| Total current assets | 224.02M |
| Goodwill | 22.86M |
| Intangible assets | 90.79M |
| Property, plant and equipment | 35.05M |
| Total assets | 370.19M |
| Accounts payable | 6.53M |
| Short/Current long term debt | 38.19M |
| Total current liabilities | 116.20M |
| Total liabilities | 371.05M |
| Shareholder's equity | -861.00K |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | 10.56M |
| Capital expenditures (TTM) | 609.00K |
| Free cash flow (TTM) | 9.95M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | -4.22% |
| Return on Invested Capital | -293.27% |
| Cash Return on Invested Capital | 186.56% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 7.70 |
| Daily high | 7.85 |
| Daily low | 7.53 |
| Daily Volume | 1.30M |
| All-time high | 27.23 |
| 1y analyst estimate | 11.14 |
| Beta | 0.94 |
| EPS (TTM) | -0.09 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 11 Mar 2026 |
Downside potential
Loading...
Downside potential data
| XERS | S&P500 | |
| Current price drop from All-time high | -72.05% | -0.89% |
| Highest price drop | -89.79% | -19.00% |
| Date of highest drop | 10 Oct 2024 | 8 Apr 2025 |
| Avg drop from high | -80.05% | -2.49% |
| Avg time to new high | - | 6 days |
| Max time to new high | 322 days | 89 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
1.26B
Marketcap category
Small-cap
Description
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
Employees
394
Website
Investor relations
-
SEC filings
CEO
Paul R. Edick
Country
USA
City
Chicago
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page